United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect

What happened

United Therapeutics, a biotechnology company, will report earnings Wednesday before market hours. Last quarter it reported revenue of $783.3 million, down 1.9% year on year, and beat analysts' earnings-per-share estimates. The market expects revenue to decline 2.1% year on year this quarter.

Confirmed

Global impact / market context

Revenue is expected to fall 2.1% year on year, which would reverse last year's 6.8% growth. Investors will compare actual sales with that expectation, because missing or beating it can change how they value the company's future profits from its drug treatments.

Analyst inference

Biogen and Gilead Sciences both beat revenue estimates in their reported results. United Therapeutics has also missed Wall Street's revenue estimates multiple times over the last two years, so investors may weigh this quarter's sales against both the expected 2.1% decline and that history.

Analyst inference

What to watch

1. United Therapeutics has missed Wall Street's revenue estimates multiple times over the last two years, so investors will watch whether this quarter's actual revenue clears the expected 2.1% year-on-year decline. Confirmed
2. Watch whether the company gives guidance on future sales and costs, which means its own forecast for upcoming revenue and expenses, since that would update investor expectations beyond this quarter. Proposed
3. Watch how the shares trade after the release; Biogen fell 1.2% despite beating estimates, showing that a revenue beat alone may not lift the stock if spending or profit per sale disappoints. Analyst inference

Evidence

• stockstory.org